Novavax received full Marketing Authorization for potype COVID-19 vaccine Nuvaxovid in UK
On Oct. 18, 2023, Novavax announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United…
Moderna announced positive top line data from phase 2/3 study of COVID-19 vaccine in children 6 to 11 years of age
On Oct. 25, 2021, Moderna announced positive interim data from the Phase 2/3 study, called the KidCOVE study,…
Moderna announced Recipharm site in France manufacturing COVID-19 Vaccine following approval by EMA
On Jul. 1, 2021, Moderna confirmed that following the European Medicines Agency’s (EMA) Committee for Human Medicines (CHMP)…
Moderna filed for conditional Marketing Approval for its COVID-19 vaccine in adolescents in the EU
On Jun. 7, 2021, Moderna announced that it had submitted for a conditional marketing approval (CMA) for its…
European Medicines Agency began rolling review of Moderna’s mRNA vaccine candidate against COVID-19
On Nov. 16, 2020, Moderna announced that the European Medicines Agency (EMA) human medicines committee (CHMP) had started…
Moderna received confirmation of eligibility for submission of MAA to the European Medicines Agency for COVID-19 vaccine
On Oct. 14, 2020, Moderna announced that it had received written confirmation from the European Medicines Agency (EMA)…